

LIST OF TABLES

Table 1. Characteristics of patients ≤ 18 years of age receiving autologous transplants for non-Hodgkin lymphoma between July 1999 and June 2018
Table 2. Characteristics of patients > 18 years of age receiving autologous transplant for non-Hodgkin lymphoma between July 1999 and June 2018
Table 3. Characteristics of patients ≤ 18 years of age receiving autologous transplants for Hodgkin's disease between July 1999 and June 2018
Table 4. Characteristics of patients > 18 years of age receiving autologous transplants for Hodgkin's disease between July 1999 and June 2018
Table 5. Characteristics of patients ≤ 18 years of age receiving autologous transplants for acute myelogenous leukemia between July 1999 and June 2018
Table 6. Characteristics of patients > 18 years of age receiving autologous transplants for acute myelogenous leukemia between July 1999 and June 2018
Table 7. Characteristics of patients ≤ 18 years of age receiving autologous transplants for acute lymphoblastic leukemia between July 1999 and June 2018
Table 8. Characteristics of patients > 18 years of age receiving autologous transplants for acute lymphoblastic leukemia between July 1999 and June 2018
Table 9. Characteristics of patients receiving autologous transplants for multiple myeloma between July 1999 and June 2018
Table 10. Characteristics of patients receiving autologous transplants for neuroblastoma between July 1999 and June 2018
Table 11. Characteristics of patients receiving autologous transplants for testicular cancer between July 1999 and June 2018
Table 12. Characteristics of patients ≤ 18 years of age receiving autologous transplants for central nervous system tumors (except CNS lymphoma and neuroblastoma) between July 1999 and June 2018
Table 13. Characteristics of patients > 18 years of age receiving autologous transplants for central nervous system tumors (except CNS lymphoma and neuroblastoma) between July 1999 and June 2018
Table 14. Characteristics of patients receiving HLA-identical sibling transplant for chronic myelogenous leukemia between July 1999 and June 2018 by disease phase
Table 15. Characteristics of patients receiving transplant other than HLA-identical sibling for chronic myelogenous leukemia between July 1999 and June 2018 by disease phase
Table 16. Characteristics of patients ≤ 18 years of age receiving HLA-identical sibling transplant for acute myelogenous leukemia between July 1999 and June 2018 by remission rate
Table 17. Characteristics of patients > 18 years of age receiving HLA-identical sibling transplant for acute myelogenous leukemia between July 1999 and June 2018 by remission state
Table 18. Characteristics of patients ≤ 18 years of age receiving transplant from donors other than HLA-identical sibling for acute myelogenous leukemia between July 1999 and June 2018 by remission state
Table 19. Characteristics of patients > 18 years of age receiving transplant from donors other than HLA-identical sibling for acute myelogenous leukemia between July 1999 and June 2018 by remission state
Table 20. Characteristics of patients ≤ 18 years of age receiving HLA-identical sibling transplant for acute lymphoblastic leukemia between July 1999 and June 2018 by remission state
Table 21. Characteristics of patients > 18 years of age receiving HLA-identical sibling transplant for acute lymphoblastic leukemia between July 1999 and June 2018 by remission state
Table 22. Characteristics of patients ≤ 18 years of age receiving transplants from donors other than HLA-identical siblings for acute lymphoblastic leukemia between July 1999 and June 2018 by remission state
Table 23. Characteristics of patients > 18 years of age receiving transplants from donors other than HLA-identical siblings for acute lymphoblastic leukemia between July 1999 and June 2018 by remission state

Table 24. Characteristics of patients receiving HLA-identical sibling transplants for myelodysplastic syndrome between July 1999 and June 2018 by disease stage
Table 25. Characteristics of patients receiving transplants from donors other than HLA-identical siblings for myelodysplastic syndrome between July 1999 and June 2018 by disease stage
Table 26. Characteristics of patients receiving HLA-identical sibling transplants for non-Hodgkin lymphoma between July 1999 and June 2018
Table 27. Characteristics of patients receiving transplants from donors other than HLA-identical siblings for non-Hodgkin lymphoma between July 1999 and June 2018
Table 28. Characteristics of patients receiving allogeneic transplants for Hodgkin's disease between July 1999 and June 2018 by donor type
Table 29. Characteristics of patients receiving HLA-identical sibling transplants for multiple myeloma between July 1999 and June 2018 by time from diagnosis to transplant
Table 30. Characteristics of patients receiving transplants from donors other than HLA-identical siblings for multiple myeloma between July 1999 and June 2018 by time from diagnosis to transplant
Table 31. Characteristics of patients \leq 18 years of age receiving allogeneic transplants for severe aplastic anemia between July 1999 and June 2018 by donor type
Table 32. Characteristics of patients $>$ 18 years of age receiving allogeneic transplants for severe aplastic anemia between July 1999 and June 2018 by donor type
Table 33. Characteristics of patients receiving allogeneic transplants for Fanconi anemia between July 1999 and June 2018 by donor type
Table 34. Characteristics of patients receiving allogeneic transplants for thalassemia between July 1999 and June 2018 by donor type
Table 35. Characteristics of patients receiving allogeneic transplants for SCID between July 1999 and June 2018 by donor type
Table 36. Characteristics of patients receiving allogeneic transplants for inherited disorders between July 1999 and June 2018 by donor type
Appendix. Abbreviations